Chronic kidney disease (CKD) is one of the fastest growing global causes of death, estimated to rank among the top five by 2040 (Foreman et al, 2018). This illustrates current pitfalls in diagnosis and management of CKD. Advanced CKD requires renal function replacement by dialysis or transplantation. However, earlier CKD stages, even when renal function is still normal, are already associated with an increased risk of premature death (Perez-Gomez et al, 2019). Thus, novel approaches to diagnose and treat CKD are needed. The histopathological hallmark of CKD is kidney fibrosis, which is closely associated with local inflammation and loss of kidney parenchymal cells. Thus, kidney fibrosis is an attractive process to develop tests allowing an earlier diagnosis of CKD and represents a potential therapeutic target to slow CKD progression or promote regression.

中文翻译：

---

PDGFR-β和肾纤维化。

慢性肾脏病（CKD）是全球增长最快的死亡原因之一，据估计到2040年将跻身前五名（Foreman等，2018）。这说明了CKD诊断和管理的当前陷阱。晚期CKD需要通过透析或移植来替代肾功能。然而，即使肾脏功能仍然正常，早期CKD阶段也已经与过早死亡的风险增加相关（Perez-Gomez等，2019）。因此，需要新颖的方法来诊断和治疗CKD。CKD的组织病理学特征是肾脏纤维化，它与局部炎症和肾实质细胞的丢失密切相关。从而，